Jay Luly Sells 4,743 Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay Luly sold 4,743 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $14.23, for a total transaction of $67,492.89. Following the sale, the chief executive officer directly owned 858,026 shares of the company’s stock, valued at $12,209,709.98. The trade was a 0.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Enanta Pharmaceuticals Price Performance

ENTA opened at $14.60 on Friday. Enanta Pharmaceuticals, Inc. has a 12-month low of $4.09 and a 12-month high of $15.34. The stock has a market capitalization of $421.36 million, a PE ratio of -3.81 and a beta of 0.96. The firm’s fifty day moving average price is $11.89 and its 200 day moving average price is $9.06.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.26. The company had revenue of $15.13 million during the quarter, compared to analyst estimates of $15.60 million. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. On average, equities research analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ENTA has been the topic of several research reports. JPMorgan Chase & Co. began coverage on Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 price objective on the stock. Jefferies Financial Group raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the company from $14.00 to $20.00 in a research report on Wednesday, October 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, October 8th. Westpark Capital boosted their target price on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, September 30th. Finally, JMP Securities raised their price target on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 12th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ENTA. Millennium Management LLC grew its position in shares of Enanta Pharmaceuticals by 50.2% during the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after acquiring an additional 449,945 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Enanta Pharmaceuticals by 2.1% during the 1st quarter. Acadian Asset Management LLC now owns 867,037 shares of the biotechnology company’s stock valued at $4,782,000 after purchasing an additional 17,613 shares during the period. Marshall Wace LLP grew its position in Enanta Pharmaceuticals by 0.8% in the 2nd quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock worth $6,482,000 after purchasing an additional 6,522 shares during the last quarter. Commodore Capital LP bought a new position in Enanta Pharmaceuticals in the 3rd quarter worth about $9,576,000. Finally, Stonepine Capital Management LLC increased its stake in shares of Enanta Pharmaceuticals by 2.3% in the second quarter. Stonepine Capital Management LLC now owns 604,066 shares of the biotechnology company’s stock valued at $4,567,000 after purchasing an additional 13,324 shares during the period. 94.99% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.